Literature DB >> 26998140

Small-lymphoid cells and myeloid antigen expression in a patient with IgG myeloma: A case report.

Pengjun Jiang1, Wen Xia1, Xuemei Sun1, Xingbin Dai1, Lin Li1.   

Abstract

Multiple myeloma is defined as a malignant proliferation of a single clone of plasma cells resulting in monoclonal immunoglobulin production. Due to the number of plasma cell morphological variants, difficulty is often faced during morphological diagnosis. The current study describes the case of a 49-year-old woman presenting with atypical plasma cell morphology detected by a bone marrow examination. Flow cytometric immunophenotyping determined the nature of the neoplastic cells as monoclonal myeloma cells with myeloid antigen expression. Serum electrophoresis with immunofixation and subsequent clinical findings confirmed this diagnosis. Therefore, the immunophenotyping of plasma cells in myelomas may be useful for the diagnosis of cases with atypical plasma cell morphology.

Entities:  

Keywords:  immunoglobulin G; myeloid antigen; myeloma; small lymphoid

Year:  2016        PMID: 26998140      PMCID: PMC4774604          DOI: 10.3892/ol.2016.4197

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

1.  CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.

Authors:  N Robillard; S Wuillème; L Lodé; F Magrangeas; S Minvielle; H Avet-Loiseau
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

Review 2.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

3.  Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma.

Authors:  Olga Pozdnyakova; Elizabeth A Morgan; Betty Li; Ali Shahsafaei; David M Dorfman
Journal:  Leuk Lymphoma       Date:  2012-04-19

4.  Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.

Authors:  Naohi Sahara; Kazunori Ohnishi; Takaaki Ono; Yuya Sugimoto; Miki Kobayashi; Kaori Takeshita; Kazuyuki Shigeno; Satoki Nakamura; Kensuke Naito; Sadahiro Tamashima; Kenji Nara; Tadasu Tobita; Akihiro Takeshita; Ryuzo Ohno
Journal:  Eur J Haematol       Date:  2006-07       Impact factor: 2.997

5.  High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.

Authors:  J Almeida; A Orfao; M Ocqueteau; G Mateo; M Corral; M D Caballero; J Blade; M J Moro; J Hernandez; J F San Miguel
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

6.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Authors:  Pei Lin; Rebecca Owens; Guido Tricot; Carla S Wilson
Journal:  Am J Clin Pathol       Date:  2004-04       Impact factor: 2.493

7.  Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

8.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Authors:  C Pellat-Deceunynck; S Barillé; G Jego; D Puthier; N Robillard; D Pineau; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

Review 9.  Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.

Authors:  Naohi Sahara; Akihiro Takeshita
Journal:  Leuk Lymphoma       Date:  2004-01

10.  Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.

Authors:  Naohi Sahara; Akihiro Takeshita; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Takeshita; Kensuke Naito; Michio Ihara; Takaaki Ono; Sadahiro Tamashima; Kenji Nara; Kazunori Ohnishi; Ryuzo Ohno
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.